AroCell nomination committee for the AGM 2021
14 december, 2020
AroCell AB (publ.) publishes the nomination committee’s composition for the AGM in 2021.
The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on May 6, 2020, consists of:• Jon Eiken, represents his own shares• Michael Lönn, represents his own shares• Mikael Jakobsson, represents his own shares• Claes Post (chairman of the board of directors)The nomination committee shall, before the annual general meeting 2021, prepare a proposal for the election of chairman and other members of the board of directors, the election of chairman of the annual meeting, the election of auditors, the determination of fees and matters pertaining thereto.For more information please visit:Nomination committee - AroCell TK 210 ELISAShareholders who wish to submit proposals to the nomination committee for the annual general meeting 2021 can do so by e-mail to info@arocell.com (header ”AroCell's nomination committee”). Proposals should be submitted to the nomination committee before January 31st, 2021.For further information, please contact:Anders Hultman, CFO at AroCellEmail: anders.hultman@arocell.comThe information was submitted for publication, through the agency of the contact person set out above, at 9.00 a.m. on December 14, 2020.
About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com
Attachments
AroCell nomination committee for the AGM 2021
Ämnen i artikeln
AroCell nomination committee for the AGM 2021
14 december, 2020
AroCell AB (publ.) publishes the nomination committee’s composition for the AGM in 2021.
The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on May 6, 2020, consists of:• Jon Eiken, represents his own shares• Michael Lönn, represents his own shares• Mikael Jakobsson, represents his own shares• Claes Post (chairman of the board of directors)The nomination committee shall, before the annual general meeting 2021, prepare a proposal for the election of chairman and other members of the board of directors, the election of chairman of the annual meeting, the election of auditors, the determination of fees and matters pertaining thereto.For more information please visit:Nomination committee - AroCell TK 210 ELISAShareholders who wish to submit proposals to the nomination committee for the annual general meeting 2021 can do so by e-mail to info@arocell.com (header ”AroCell's nomination committee”). Proposals should be submitted to the nomination committee before January 31st, 2021.For further information, please contact:Anders Hultman, CFO at AroCellEmail: anders.hultman@arocell.comThe information was submitted for publication, through the agency of the contact person set out above, at 9.00 a.m. on December 14, 2020.
About AroCell
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser: Certifiedadviser@redeye.se, +46 (0)8 121 576 90. For more information; www.arocell.com
Attachments
AroCell nomination committee for the AGM 2021
Ämnen i artikeln
Fondernas placeringar
Placeras aktieanalyser
-992x558.png&w=3840&q=75)
Aktieråd
-160x160.jpg&w=3840&q=75)
Fondernas placeringar
Placeras aktieanalyser
Aktieråd
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
